Growth Factors and Empiric Therapy with Antibiotics: Should They Be Used Concurrently?
Authors: Stephen C. Schimpff
Journal: Annals of Internal Medicine (1994)

Editorials1 October 1994Growth Factors and Empiric Therapy with Antibiotics: Should They Be Used Concurrently?Stephen C. Schimpff, MDStephen C. Schimpff, MDUniversity of Maryland Medical Center; Baltimore, MD 21201-1595Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-121-7-199410010-00011 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Two colony-stimulating factors—or hematopoietic growth factors—are commercially available: human recombinant granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). These compounds are used frequently by oncologists to reduce the nadir of chemotherapy-induced neutropenia or hasten the recovery of normal neutrophil counts after chemotherapy in the hope that infection will not develop or that febrile neutropenia will quickly resolve. Based on current knowledge, what should be the rational use of these cytokines?Aggressive chemotherapy with or without total body radiation leads to leukopenia, among other side effects. Infection is the major consequence of neutropenia. Infection incidence and severity have an inverse ...References1. Schimpff SC. Infections in the cancer patient—diagnosis, prevention, and treatment. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York: Churchill Livingstone; 1994 (In press). Google Scholar2. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-1. N Engl J Med 1992; 327:28-35. Google Scholar3. Lieschke GJ, Burgess AW. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor-2. N Engl J Med. 1992; 327:99-106. Google Scholar4. Antman KS, Griffin JD, Elias A, Socinski MA, Ryan L, Cannistra SA, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on chemotherapy-induced myelosuppression. N Engl J Med. 1988; 319:593-8. Google Scholar5. Gabrilove JL, Jakubowski A, Scher H, Sternberg C, Wong G, Grous J, et al. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med. 1988; 318:1414-22. Google Scholar6. Nemunaitis J, Singer JW, Buckner CD, Hill R, Storb R, Thomas ED, et al. Use of recombinant human granulocyte-macrophage colony-stimulating factors in autologous marrow transplantation for lymphoid malignancies. Blood. 1988; 72:834-6. Google Scholar7. Frei E 3d, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med. 1980; 69:585-94. Google Scholar8. Hurd DD. Bone marrow transplantation for cancer: an overview. In: Schimpff SC, Klastersky J, eds. Infectious Complications in Bone Marrow Transplantation. Berlin: Springer-Verlag; 1993: 1-14. Google Scholar9. Peters WP, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C, et al. Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood. 1993; 81:1709-19. Google Scholar10. Brandt SJ, Peters WP, Atwater SK, Kurtzberg J, Borowitz MJ, Jones RB, et al. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on hematopoietic reconstitution after high-dose chemotherapy and autologous bone marrow transplantation. N Engl J Med. 1988; 318:869-76. Google Scholar11. Broun ER, Gonin R, Kneebone P, Danielson C, Cometta K, Cunningham I, et al. A randomized trial of the addition of peripheral blood progenitor cells (PBPC) to autologous bone marrow (ABM) in patients undergoing high dose chemotherapy with autologous progenitor support for breast and germ cell cancer (GCT) (Abstract). 13th Annual Meeting of the American Society of Clinical Oncology, Dallas, Texas; 1994; 13:433. Google Scholar12. Gulati SC, Bennett CL. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as adjunct therapy in relapsed Hodgkin disease. Ann Intern Med. 1992; 116:177-82. Google Scholar13. Pizzo PA. Management of fever in patients with cancer and treatment-induced neutropenia. N Engl J Med. 1993; 328:1323-32. Google Scholar14. Maher DW, Lieschke GJ, Green M, Bishop J, Stuart-Harris R, Wolf M, et al. Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med. 1994; 121:492-501. Google Scholar15. Schimpff SC. Gram-negative bacteremia. Support Care Cancer. 1993; 1:5-18. Google Scholar16. EORTC International Antimicrobial Therapy Cooperative Group. Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med. 1987; 317:1692-8. Google Scholar17. Steinbeck MJ, Roth JA. Neutrophil activation by recombinant cytokines. Rev Infect Dis. 1989; 11:549-68. Google Scholar18. Roilides E, Pizzo PA. Modulation of host defenses by cytokines: evolving adjuncts in prevention and treatment of serious infections in immunocompromised hosts. Clin Infect Dis. 1992; 15:508-24. Google Scholar Author, Article, and Disclosure InformationAuthors: Stephen C. Schimpff, MDAffiliations: University of Maryland Medical Center; Baltimore, MD 21201-1595Corresponding Author: Stephen C. Schimpff, MD, University of Maryland Medical Center, 22 South Greene Street, Baltimore, MD 21201. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoFilgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial Darryl W. Maher , Graham J. Lieschke , Michael Green , James Bishop , Robin Stuart-Harris , Max Wolf , William P. Sheridan , Richard F. Kefford , Jonathan Cebon , Ian Olver , Joseph McKendrick , Guy Toner , Kenneth Bradstock , Marian Lieschke , Scott Cruickshank , Dianne K. Tomita , Eric W. Hoffman , Richard M. Fox , and George Morstyn Metrics Cited byTherapy of Infections in Cancer PatientsFebrile Neutropenie: Praktische AspekteSupportive Therapie mit ZytokinenTherapy of Febrile Neutropenia: An Algorithm for Current Clinical Attitudes Taking into Account Cost BenefitEmpiric therapy of bacterial infections in severe neutropeniaSupportive Therapie mit Zytokinen 1 October 1994Volume 121, Issue 7Page: 538-540KeywordsAntibioticsBacteremiaChemotherapyCytokinesGranulocyte colony stimulating factorGranulocyte macrophage colony stimulating factorGranulocytesGrowth factorsNeutropeniaNeutrophils ePublished: 15 August 2000 Issue Published: 1 October 1994 Copyright & PermissionsCopyright © 1994 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...